Notice (B): Government-Owned Inventions; Availability for Licensing

Federal Register: January 28, 2010 (Volume 75, Number 18)             
                  Page 4570-4571

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Signal-to-Noise Enhancement in Imaging Applications Using a Time-Series 
of Images

    Description of Invention: The invention offered for licensing 
relates to the field of imaging and specifically to the field of 
medical imaging. The apparatus and method of the invention provide for 
noise reduction in imaging applications that use a time-series of 
images. In one embodiment of the invention, a time-series of images is 
acquired using a same imaging protocol of the same subject area, but 
the images are spaced in time by one or more time intervals (e.g. 1, 2, 
3 * * * seconds apart). A sub-region is projected across

[[Page 4571]]

all of the images to perform a localized analysis (corresponding X-Y 
pixels or X-Y-Z voxels are analyzed across all images) that identifies 
temporal components within each sub-region. Subsequently, within the 
sub-regions, only those temporal components are selected whose 
amplitude is above a predetermined amplitude threshold. The images are 
then reconstructed using the sub-regions with reduced components. A 
maximal-intensity-projection (MIP) is applied in the temporal domain 
(tMIP) in order to obtain a single image with reduced noise (this can 
be done either at the sub-region level or at the reconstructed image 
level). The technology can be applied to a broad spectrum of medical 
imaging technologies such as MRI, X-Ray, CT and others.
    Applications: Medical imaging and diagnostics applied to MRI, X-
Ray, CT scans or other imaging modalities including PET, SPECT, 
ultrasound or optical.
    Advantages: Enhancing signal-to-noise of medical imaging 
techniques.
    Development Status:
     Proof of concept has been demonstrated. Data is available.
     Need to acquire further data to establish clinical utility 
of the method and to further optimize the protocol.
    Market:
     According to market research reports the market for 
medical imaging equipment industry in the United States is 
approximately $9.0 billion dollars now and has been growing by 
approximately 7.6% annually.
     The United States market for computed tomography (CT) 
scanning systems is estimated to touch $3.6 billion by the end of 2009. 
The U.S. accounts for over 50.0% of the worldwide market.
     Worldwide MRI equipment market is estimated to reach $5.5 
billion by 2010, according to new report by Global Industry Analysts, 
Inc. (http://www.strategyr.com/Magnetic_Resonance_Imaging_MRI_
Equipment_Market_Report.asp). In the United States the market for 
such equipment is estimated at $1.9 billion for 2008, as stated the 
same report. The very high-field MRI systems market in the United 
States is projected to reach $968 million by the year 2010. Very High-
Field Systems also represent the fastest growing segment, as hospitals 
and clinics upgrade old equipment with state-of-the-art systems.
     Enhancements in imaging technologies to achieve better 
image clarity, reliability and speed are being constantly pursued by 
medical imaging companies. Technologies that offer such improvements 
therefore present excellent commercial potential. Thus the subject 
invention which can be applied in a broad spectrum of imaging 
technologies offers such good commercial potential.
    Inventors: Han Wen and Vinay Pai (NHLBI).
    Relevant Articles:
    1. Fish DA, Grochmalicki J, Pike ER. Scanning singular-value-
decomposition method for restoration of images with space-variant blur. 
J Opt Soc Am A, 13(3), pp. 464-469, March 1996.
    2. Du X, Dunxu Y, Cuihua L, Jing L. ``A novel approach to SVD-based 
image filtering improvement,'' International Conference on Computer 
Science and Software Engineering, vol 6, pp. 133-136, 2008.
    Patent Status: U.S. Provisional Application No. 61/266,442 filed 
December 3, 2009, entitled ``Signal-to-Noise Enhancement in Imaging 
Applications Using a Time-Series of Images'' (HHS Reference No. E-292-
2009/0-US-01).
    Related Technologies: Image denoising techniques such as singular 
value decomposition (SVD).
    Licensing Status: Available for licensing.
    Licensing Contacts: Uri Reichman, Ph.D., MBA; 301-435-4616; 
UR7a@nih.gov; or John Stansberry, Ph.D.; 301-435-5236; 
stansbej@mail.nih.gov.
    Collaborative Research Opportunity: The National Heart, Lung, and 
Blood Institute is seeking statements of capability or interest from 
parties interested in collaborative research to implement the 
technology described above on specific commercial platforms. Please 
contact Denise Crooks, Ph.D. at 301-435-0103 or via e-mail at 
crooksd@nhlbi.nih.gov for more information.

Method for the Treatment of HIV/AIDS Infection Using Acyclovir in 
Identified Subjects

    Description of Invention: The invention provides the novel method 
to treat HIV infections with acyclovir which can be converted to 
acyclovir triphosphate inside infected cells. Acyclovir or acyclovir-
related drugs were previously approved for control of herpesvirus 
replication with 20 years of records of safe application. The subject 
invention demonstrates that acyclovir triphosphate can inhibit HIV-1 
reverse transcriptase as a potent suppressor of HIV-1 replication in 
human lymphoid tissues. In addition, the subject invention may be 
attractive to potential licensees, as there is little to no FDA hurdle 
to overcome in the development of the new formulations to use in this 
manner. Thus, the low cost and proven safety of acyclovir may lead to a 
new medicine for treating HIV-1 infections and a prophylactic agent for 
preventing HIV infections.
    Applications: The treatment and prevention of HIV infections.
    Development Status: In vitro data available.
    Inventors: Leonid B. Margolis, Andrea Lisco, Christophe Vanpouille, 
Jean-Charles Grivel (NICHD).
    Related Publications:
    1. A Lisco et al. Acyclovir is activated into a HIV-1 reverse 
transcriptase inhibitor in herpesvirus-infected human tissues. Cell 
Host Microbe. 2008 Sep 11;4(3):260-270. [PubMed: 18779052]
    2. N Nagot et al. Reduction of HIV-1 RNA levels with therapy to 
suppress herpes simplex virus. New Engl J Med. 2007 Feb 22;356(8):790-
799. [PubMed: 17314338]
    Patent Status: PCT Application No. PCT/US2008/010316 filed 30 Aug 
2008, which published as WO 2009/032244 on 12 Mar 2009 (HHS Reference 
No. E-306-2007/0-PCT-02).
    Licensing Status: Available for licensing.
    Licensing Contact: Sally Hu, Ph.D.; 301/435-5606; HuS@mail.nih.gov.
    Collaborative Research Opportunity: The Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, Program in 
Physical Biology, Section on Intracellular Interactions, is seeking 
statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
this technology. Please contact Joseph Conrad, Ph.D., J.D. at 301-435-
3107 or jmconrad@mail.nih.gov for more information.

    Dated: January 21, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-1669 Filed 1-27-10; 8:45 am]
BILLING CODE 4140-01-P